Tandem Health has raised $100 million in a Series B led by the Scaleup Europe Fund, the EU-backed vehicle's first healthtech investment and one of the largest rounds a European clinical AI company has closed this year.

Kinnevik, Northzone, Amino Collective and Visionaries also joined the round. The Stockholm company has now raised $160 million in total, following a $50 million Series A in 2025, and employs roughly 170 people.

From scribe to operating system

Tandem Health started where most clinical AI companies start: ambient documentation. Its tool listens during a patient consultation and produces the medical note, along with referral letters and patient communications, removing the after-hours paperwork that has become one of the loudest complaints in European medicine.

The ambition attached to this round is larger. The company says the capital will go toward what it calls an AI-native clinic operating system — software that manages patient flows and runs agents across additional clinical tasks, rather than sitting beside the consultation as a transcription layer.

That distinction matters commercially. Documentation tools are increasingly crowded and increasingly commoditized; the workflow layer underneath a clinic is stickier and harder to rip out.

The scale it already has

Tandem Health says its product is used by 10,000 care organizations across 14 European markets, with the United Kingdom its largest market by user numbers. That footprint is the argument for the round: the company is not buying its way into European healthcare so much as extending a position it already holds.

Why the EU fund showed up

The Scaleup Europe Fund is a €5 billion instrument built to keep European technology companies growing on the continent rather than selling early or relocating to raise later-stage money. Choosing a healthtech company for its first deal in the category is a statement about where the bloc thinks its leverage sits.

Chief executive and co-founder Lukas Saari framed it in those terms. "Europe should be setting the standard for how AI enters healthcare, not adopting someone else's," he said.

The subtext is familiar to anyone watching the sector: American clinical AI companies have raised larger rounds and moved faster, and European health systems are buying from them. Regulatory divergence and data residency rules give a home-grown vendor an opening, but only if it has the capital to move at the same speed.

What to watch

The gap between an ambient scribe and a clinic operating system is a product gap, not a funding gap, and it is where a number of well-financed companies have stalled. Documentation is a contained problem with a clear output. Patient flow touches scheduling, staffing, billing and clinical judgment, and it puts a vendor much closer to decisions that health systems are careful about delegating.

With $160 million raised and presence in 14 markets, Tandem Health has the distribution to attempt it. Whether European clinics let software that writes their notes start routing their patients is the question the next two years will answer.

Source

Tech.eu — "Swedish healthtech Tandem Health scores $100M Series B, led by EU's €5bn tech startup fund"